Quarterly results round-up: Baxter weighed down by unfavourable exchange rates; BIM, ISRG, LH, NVS
This article was originally published in Clinica
Executive Summary
Like its peers Johnson & Johnson and Abbott, Baxter International's top line has been dented by foreign exchange rates: Baxter reported second-quarter revenues of $3.6bn, up 4% on a constant currency basis, but just 1% on a reported basis. Also the firm's two business units, medical products and bioscience, both grew 1% (+4% constant currency) to $2.0bn and $1.6bn, respectively.